Xplora completed a NOK150m private placement at NOK52 per share — a reasonable 6.
Redeye comments on AlzeCure Pharma presenting new preclinical data for NeuroRestore ACD856 at the AD...
CapMan continues its strategic execution towards EUR 10bn in AUM by launching Infrastructure debt op...
Redeye is encouraged by FluoGuide receiving FDA Fast Track Designation for FG001 in High-Grade Gliom...
Redeye comments on Isofol’s expansion of its arfolitixorin license to include autism spectrum disord...
Redeye is positive to AAC’s press release today, which states an expected order value of more than E...
Redeye comments on Scandinavian Chemotech announcing that its subsidiary Scandinavian Meditech has r...
Lower volumes mask an improved earnings profile, as Alcadon benefits from exiting its loss-making Ge...
We hosted an investor event with Gofore management that focused on how AI is changing the IT service...
Redeye comments on Sprint Bioscience's announcement of positive preclinical proof-of-concept data fo...
Redeye returns with an update following SciBase Holding’s Q4 report.
* 300k phones sold annually with +30% GM * Same playbook as Doro: add subscriptions * Price not disc...
Xplora has acquired Emporia, the leading provider of senior mobile phones in the DACH region, enhanc...
Redeye attended an analyst meeting with Evolution on Friday and provides its key takeaways from the ...
Investmentbolaget Creades har länge varit synonymt med tillväxt och historisk premievärdering.
Redeye leaves a comment following Cinclus’ announcement that it has secured a structured growth-debt...
Redeye provides an initial comment on SciBase's Q4 report, where sales came in somewhat above our es...
Redeye attended an analyst meeting with Hacksaw yesterday, which included a studio tour, game demos,...
Investors House announced three separate changes today.
